Item 7.01. Regulation FD Disclosure
On October 8, 2009, Nektar Therapeutics ("Nektar") and AstraZeneca received
early termination of the waiting period under the Hart-Scott-Rodino Act in
connection with their worldwide agreement for NKTR-118 and NKTR-119. Expiration
of the waiting period triggers the effectiveness of the agreement and the
up-front payment to Nektar of $125 million. Please refer to the Form 8-K Current
Report filed by Nektar with the Securities and Exchange Commission on September
21, 2009, for a description of the agreement between AstraZeneca and Nektar.
Add
NKTR to Portfolio
Set Alert
Email to a
Friend